Dietmar W. Siemann

Dietmar W. Siemann

Auto-generated profile, based on publicly available information

Dietmar W. Siemann

Department of Radiation Oncology, University of Florida, Gainesville, FL 32610, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

2 June 2004 in Cancer
Verified
Journal Article
Closed access
PDF file
DSDietmar W. Siemann
Dietmar W. Siemann
DCDavid J. Chaplin
David J. Chaplin
MHMichael Robert Horsman
Michael Robert Horsman

21 January 2009 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
DSDietmar W Siemann
Dietmar W Siemann
DCDavid J Chaplin
David J Chaplin
PWPatricia A Walicke
Patricia A Walicke
Vascular-disrupting strategies impair a tumor's blood vessel network, which is essential for tumor progression and metastasis. Vascular-disrupting agents (VDAs) cause a rapid and selective vascular...

15 January 2005 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DSDietmar W. Siemann
Dietmar W. Siemann
MBMichael C. Bibby
Michael C. Bibby
GDGraham G. Dark
Graham G. Dark
ADAdam Paul Dicker
Adam Paul Dicker
FEFerry A.L.M. Eskens
Ferry A.L.M. Eskens
PLPatricia M. LoRusso
Patricia M. LoRusso
The therapeutic potential of targeting the tumor vascular supply is now widely recognized. Intense research and development activity has resulted in a variety of investigational agents, a number of which are currently in clinical development. As these novel agents are quite distinct from the cytotoxic drugs conventionally used in the treatment of solid tumors, it will be particularly important to ensure early differentiation of these vascular-targeted therapies in order to encourage widespread understanding of their potential benefits and application in the clinic. Two distinct groups of vascular-targeted therapies have evolved: antiangiogenic agents and vascular-disrupting approaches. These differ in three key respects: their physiologic target, the type or extent of disease that is likely to be susceptible, and the treatment scheduling. Inhibitors of angiogenesis interfere with new vessel formation and therefore have a preventative action, require chronic administration, and are likely to be of particular benefit in early-stage or asymptomatic metastatic disease. Vascular-disrupting agents target the established tumor blood vessels, resulting in tumor ischemia and necrosis. These agents are therefore given acutely, show more immediate effects, and may have particular efficacy against advanced disease. It is essential that these agents can be readily distinguished from conventional therapies and that an understanding of key differences between the two types of vascular-targeted therapies is fostered. Here, a simple taxonomy and nomenclature is proposed in anticipation that the therapeutic potential of this novel class can be realized as these approaches advance in clinical settings and a new anticancer strategy becomes available in the clinic.

1 November 2015 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
DSDhivya R. Sudhan
Dhivya R. Sudhan
DSDietmar W. Siemann
Dietmar W. Siemann

1 September 2015 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
DSDietmar W. Siemann
Dietmar W. Siemann
MHMichael Robert Horsman
Michael Robert Horsman